From: Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
 | All Agents | Apixaban (N = 15) | Rivaroxaban (N = 14) | Dabigatran (N = 3) | P value € |
---|---|---|---|---|---|
Age, years | 30–84 (median 65) | 31–80 (median 67) | 30–84 (median 60) | 57–77 (median 66) | 0.64 |
Gender | 16 male, 16 female | 7 male, 8 female | 8 male, 6 female | 1 male, 2 female | 0.71 |
AF indication, N (%) | 16 (50%) | 6 (43%) | 9 (60%) | 1 (33%) | 0.59 |
VTE indication, N (%) | 16 (50%) | 9 (57%) | 5 (40%) | 2 (66%) | 0.59 |
Nosebleeds improved, N | 1 | 0 | 0 | 1 } | 0.044 |
Nosebleeds unchanged, N | 7 | 4 | 2 | 1 } | |
Worse but tolerable, N | 13 | 7†| 5 | 1 } | |
Worse, treatment discontinued, N | 11 ‡ | 4 | 7 | 0 } |